The acrs stock forecast suggests that strong biotech ETF inflows may sustain momentum. With volatility at 28%, traders could see sharp intraday swings, but long-term holders may benefit from upcoming pipeline news. We can report that insiders do own shares in Aclaris Therapeutics, Inc.. As individuals, the insiders collectively own US$5.6m worth of the US$207m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time , and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Investors tracking acrs stock forecast note Q2 revenue up 23% year-over-year, signaling operational strength. The chart pattern suggests possible breakout above the $8.50 resistance if market sentiment in biotech stays positive over the next month.